Analyst Research

Report Title Price
Bioporto A/S: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
Wright Investors Service Comprehensive Report for BioPorto A/S
Provider: Wright Reports
$472.00
Buy
BioPorto Diagnostics A/S (BIOPOR) - Financial Analysis Review
Provider: GlobalData
$75.00
Buy
BioPorto Diagnostics A/S (BIOPOR) - Medical Equipment - Deals and Alliances Profile
Provider: GlobalData
$50.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

BioPorto A/S Maintains FY 2012 Financial Guidance


Friday, 25 May 2012 05:22am EDT 

BioPorto A/S announced that its expectations for fiscal year 2012 remain unchanged. The Company still expects to report fiscal year 2012 revenues from product sales to grow to a range of between DKK 25 million and DKK 30 million, and fiscal year 2012 sales of The NGAL Test are expected to exceed DKK 10 million. The Company also still expects to report fiscal year 2012 net loss in a range of between DKK 10 million and DKK 12 million. 

Latest Developments for Bioporto A/S

Latest Key Developments in Pharmaceuticals

Company Quote

Bioporto A/S
(BIOPOR.CO)
1.67
-0.18 -9.73%
19 Jun 2013